Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer

Conditions:   Carcinoma, Squamous Cell of Head and Neck;   Oropharynx Squamous Cell Carcinoma
Interventions:   Drug: Nivolumab Injection;   Radiation: Radiotherapy (RT)
Sponsors:   Robert Ferris;   Bristol-Myers Squibb
Not yet recruiting

https://ift.tt/2z0kzUn